Verus will realign strategy to concentrate on pediatric diseases with unmet needs with initial $30 million payment.

AstraZeneca acquired Verus Pharmaceuticals’ pediatric asthma development programs for $30 million. Verus will also receive development expense reimbursements and a potential earn-out payment of $280 million.

Verus, a pediatric-oriented company, plans to refocus on developing therapeutics for unmet needs associated with related atopic diseases and conditions, comments Robert Keith, president and COO of the company.

Through the transaction, AstraZeneca will gain North American rights to a Captisol® enabled budesonide solution, a short-acting beta agonist therapy, and a customized version of eFlow® for use with both medications.

Previous articleCepheid to Develop Cervical Cancer Test with HPV Technology from Quantovir
Next articleBristol-Myers Squibb Shells Out $430M for Adnexus